#LibraryResource

Active surveillance in #ProstateCancer: The 2021 @NCCN controversy. A #LibraryResource article from @zklaassen_md @GACancerCenter and @WallisCJD @UofT. #ReadNow on UroToday >

The current landscape of PSMA PET imaging in #ProstateCancer: Evolution of next-generation imaging & PSMA PET for primary tumor evaluation. #LibraryResource article by @WallisCJD, @zklaassen_md, and @rksayyid on UroToday >

Prostate radiotherapy for de novo, low volume metastatic hormone-sensitive #ProstateCancer: Is there a benefit? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss available evidence in this space >

Prostate radiotherapy for de novo, low volume metastatic hormone-sensitive #ProstateCancer: Is there a benefit? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss available evidence in this space >

BCG-unresponsive non-muscle invasive #BladderCancer: Immune checkpoint inhibitors. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss currently available evidence and key ongoing studies >

The impact of surgeon experience and volume on patient outcomes in radical prostatectomy patients. #LibraryResource @zklaassen_md @GACancerCenter and @RKSayyid @UofT highlight current evidence on UroToday >

The current landscape of neoadjuvant immunotherapy agent combinations in patients with clinically localized, muscle-invasive #BladderCancer. #LibraryResource @rksayyid @UofT and @zklaassen_md @GACancerCenter discuss on UroToday >

The current landscape of metastatic castration-resistant #ProstateCancer: Immunotherapy and targeted therapies. #LibraryResource article by @WallisCJD, @rksayyid @UofTUrology, @zklaassen_md @GACancerCenter on UroToday >

Treatment intensification in metastatic hormone-sensitive #ProstateCancer cases - Synchronous high volume #mHSPC. #LibraryResource article from @rksayyid, @zklaassen_md, and @WallisCJD on UroToday > @GACancerCenter @UofTUrology

#ArtificialIntelligence and #ProstateCancer: Risk stratification after primary therapy, ADT treatment intensification, and evaluation of metastatic disease. #LibraryResource @zklaassen_md and @RKSayyid discuss contemporary literature on UroToday >

Exciting news in low-grade Ta #NMIBC management! 🚀 UGN-102 offers hope for fewer TURBTs, better quality of life. Results from Optima II and ATLAS trials look promising. #LibraryResource @zklaassen_md @RKSayyid . #ReadNow >

The current landscape of neoadjuvant therapy in patients with #UTUC. #LibraryResource @rksayyid and @zklaassen_md discuss the latest evidence for neoadjuvant systemic therapy options in patients with #UrothelialCarcinoma of the upper tracts >

First-line therapy for metastatic clear cell renal cell carcinoma #ccRCC. #LibraryResource article by @zklaassen_md @GACancerCenter and @WallisCJD @VUMChealth on the treatment landscape for metastatic #RCC. #ReadNow on UroToday > #KidneyCancerAwareness

The treatment landscape of metastatic #UrothelialCarcinoma: Second-line systemic therapy. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss treatment options for patients in the second-line setting. #ReadNow >

PARP inhibitor + AR signaling inhibitor combinations: Will this be the future of #mCRPC first-line therapy? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss data from the #PROpel, #MAGNITUDE, and #TALAPRO2 trials on UroToday >

Radiotherapy in #ProstateCancer: Utilization of adjuvant and salvage radiotherapy. #LibraryResource @rksayyid @UofT and @zklaassen_md @GACancerCenter discuss recent evidence and the role of concurrent androgen suppression in this setting on UroToday >

Novel treatment options for BCG naïve nonmuscle-invasive #BladderCancer: immune priming and immune checkpoint inhibitors. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss the current state of the evidence for ongoing trials >

#ArtificialIntelligence and #ProstateCancer: Risk stratification after primary therapy, ADT treatment intensification, and evaluation of metastatic disease. #LibraryResource @zklaassen_md and @RKSayyid discuss contemporary literature on UroToday >

Novel treatment options for BCG naïve nonmuscle-invasive #BladderCancer: immune priming and immune checkpoint inhibitors. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss the current state of the evidence for ongoing trials >

The impact of surgeon experience and volume on patient outcomes in radical prostatectomy patients. #LibraryResource @zklaassen_md @GACancerCenter and @RKSayyid @UofT highlight current evidence on UroToday >